Marotta Asset Management Has $463,000 Stake in Johnson & Johnson (NYSE:JNJ)

Marotta Asset Management reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 3.7% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,854 shares of the company’s stock after selling 110 shares during the quarter. Marotta Asset Management’s holdings in Johnson & Johnson were worth $463,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Innealta Capital LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $27,000. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $44,000. MFA Wealth Advisors LLC acquired a new stake in Johnson & Johnson in the second quarter worth $43,000. Grayhawk Investment Strategies Inc. grew its holdings in shares of Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the period. Finally, Fairfield Financial Advisors LTD bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $46,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of several research analyst reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Friday, September 20th. Sanford C. Bernstein boosted their price target on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Finally, TD Securities decreased their price objective on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Price Performance

Shares of JNJ opened at $160.50 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The company’s fifty day simple moving average is $162.61 and its 200 day simple moving average is $154.30. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a market cap of $386.27 billion, a price-to-earnings ratio of 10.01, a PEG ratio of 2.69 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. During the same period in the prior year, the firm earned $2.80 EPS. Johnson & Johnson’s quarterly revenue was up 4.3% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.09%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.